Tag Archives: study

Breast density helps better predict breast cancer risk — ScienceDaily

The study, “Volumetric Breast Density Improves Breast Cancer Risk Prediction,” was presented during the 2014 San Antonio Breast Cancer Symposium. “There is increasing interest in implementing personalized breast cancer screening strategies instead of guidelines based on a woman’s age. However, most risk models do not include breast density, which is an important indicator of a woman’s breast cancer risk,” said Jennifer Harvey, MD, professor of radiology at the UVA School of Medicine…

Senescent cells play an essential role in wound healing

“What is most exciting is that we are now able to identify what senescent cells express that makes them beneficial,” said Campisi, senior scientist on the study. “This means we will be able to simply provide that factor while we eliminate senescent cells to prevent a deleterious side effect before it even occurs.” Postdoctoral fellow, Marco Demaria, PhD, lead author of the study, used two different mouse models: in the first, which was developed in collaboration with colleagues at the Erasmus, Harvard and Einstein Medical Schools, senescent cells can be visualized and eliminated in living animals; in the second, which was developed by Eiji Hara, Naoko Ohtani and colleagues at the Japanese Foundation for Cancer Research, mutations in two key genes block the senescence program…

Tamoxifen reduces breast cancer rates by nearly a third for 20 years — ScienceDaily

The IBIS-I trial (International Breast Cancer Intervention Study), led by Queen Mary University of London and funded by Cancer Research UK, examined the long-term risks and benefits of taking tamoxifen to prevent breast cancer in women at high risk of the disease (aged 35-70 years old, primarily with a family history of breast cancer). During the study 7,154 pre and post-menopausal women were randomized to receive either tamoxifen (20mg daily) or a matching placebo for five years. After completing treatment, the health of all participants was monitored with an average follow-up time of 16 years and maximum of 22 years. The new and extended analysis, presented at the San Antonio Breast Cancer Symposium, revealed 251 women from the tamoxifen group versus 350 from the placebo group developed breast cancer — a reduction of 29 per cent. …

Women with dense breasts will have to look beyond ultrasound for useful supplemental breast cancer screening — ScienceDaily

In a study released Monday in the Annals of Internal Medicine, Tosteson and colleagues, including lead author Brian Sprague, MD, provide evidence on the benefits and harms of adding ultrasound to breast cancer screening for women who have had a negative mammogram and also have dense breasts. The study will help inform the national legislative discussion about potential regulations requiring health providers to tell women if their mammogram shows that they have dense breasts. …

New drug combination for advanced breast cancer delays disease progression

The trial enrolled 118 post-menopausal women with metastatic hormone-receptor-positive breast cancer whose cancer continued to progress after being treated with an aromatase inhibitor. The study, based on work done by Doris Germain of Mt. Sinai Hospital, found that the combination of the drugs bortezomib and fulvestrant — versus fulvestrant alone — doubled the rate of survival at 12 months and reduced the chance of cancer progression overall. Bortezomib, used most commonly in treating multiple myeloma, is a proteasome inhibitor that prevents cancer cells from clearing toxic material…

Increased use of hypofractionated whole-breast irradiation for patients with early-stage breast cancer — ScienceDaily

An analysis of randomized trials demonstrated that patients with early-stage breast cancer who are treated with breast-conserving surgery and adjuvant whole-breast irradiation have improved survival and a lower risk of tumor recurrence compared to patients who are not treated with radiation therapy. Patients are commonly treated with CF-WBI; however, several recent randomized trials[2-5] have confirmed that patients treated with HF-WBI have similar disease-free and overall survival rates as those treated with CF-WBI. CF-WBI delivers a total dose of 45-50 Gy in 25-28 daily fractions of 1.8-2.0 Gy over five to six weeks, while HF-WBI uses a shorter treatment course and a lower total dose and number of fractions, delivering a total dose of 39-42.5 Gy in 13-16 daily fractions of 2.5-3.2 Gy over three to five weeks. This study, “Adoption of Hypofractionated Whole-Breast Irradiation for Early-Stage Breast Cancer: A National Cancer Data Base Analysis,” is a retrospective review of 113,267 early-stage breast cancer patients in the National Cancer Data Base (NCDB) from 2004 to 2011 who were treated with radiation therapy and were eligible to receive HF-WBI, and examines the use of HF-WBI compared to CF-WBI and the factors, including facility type and patient’s distance from the radiation treatment center, that influenced which type of WBI the patient received. …

Experience counts with radiation therapy for head and neck cancer, study shows

Published in the Journal of Clinical Oncology with an accompanying editorial, the study compared survival and other outcomes in 470 patients treated with radiation therapy at 101 treatment centers through a clinical trial held from 2002 to 2005. The trial was sponsored by the National Cancer Institute and organized by the Radiation Therapy Oncology Group (RTOG). The findings indicated that patients treated at the less-experienced centers were more likely to have cancer recurrence (62 percent versus 42 percent at five years) and had poorer overall survival compared with those at the highly-experienced centers (51 percent versus 69 percent five-year survival, respectively)…

HPV vaccine, riskier sexual activity not linked, Canadian researchers say

There are concerns the vaccine, which guards against four types of the HPV shown to cause cervical cancer and anogenital warts, may give girls a false sense of security about contracting sexually transmitted infections (STIs) and lead them to engage in riskier sexual activity. “These findings suggest fears of increased risky sexual behaviour following HPV vaccination are unwarranted and should not be a barrier to vaccinating at a young age,” says Dr. Smith, the lead author on the study that was published in the Canadian Medical Association Journal. This study looked at a cohort of 260,493 girls, of whom about half (128,712) were eligible for Ontario’s publicly funded, school-based HPV vaccination program during the first two school years it was offered (2007-08 and 2008-09). …